Janssen Korea's CEO, Oak-Yeon Kim faces potential criminal charges and three years in jail under the Korean Pharmaceutical Affairs Act because the manufacturer continued selling the two types of Children's Tylenol syrup that contained amounts of acetaminophen (active ingredient in Tylenol) in excess of that which was described on the label. The applicable sections of the Korean Pharmaceutical Affairs Act include: Articles 56, 58, 62, 69, 93, 94.
Although the Korean Times maintains that no adverse reactions have been reported, excessive amounts of acetaminophen were potentially contained in 38,000 bottles sold of the Children's Tylenol syrups, which could lead to liver damage.
CEO of J&J OTC Unit in Korea Faces Criminal Action over Plant Foul-Up
J&J Halts Tylenol Production In South Korea Over Mishap
Millions of J&J OTC medications recalled and an FDA consent decree
Janssen Korea CEO Faces Legal Action